Press "Enter" to skip to content

High-cost Gilead cell therapy proves durable for some lymphoma patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/SXfXu4b3GcM/high-cost-gilead-cell-therapy-proves-durable-for-some-lymphoma-patients-idINKBN1O10NG

Also Read:   Bristol-Myers defends Celgene bet as investor criticism grows